Literature DB >> 29850111

Clinical and molecular characteristics of unicentric mediastinal Castleman disease.

Antoine Legras1,2, Anne Tallet3, Audrey Didelot2, Aurélie Cazes4,5, Claire Danel4, Angela Hin5, Raphaël Borie6, Bruno Crestani5,6, Yves Castier5,7, Patrick Bagan1,8, Françoise Le Pimpec-Barthes1, Marc Riquet1, Hélène Blons2,3, Pierre Mordant5,7.   

Abstract

BACKGROUND: Unicentric mediastinal Castleman disease (CD) is a rare condition, poorly characterized due to the small number of cases and the absence of genomic study. We analyzed clinical, radiological, histological and genomic patterns associated with mediastinal CD in a substantial case series.
Methods: We retrospectively reviewed cases of unicentric mediastinal CD managed in 2 French thoracic surgery departments between 1988 and 2012. Clinical, radiological, surgical and pathological data were recorded. On available FFPE blocks we performed mutation screening by next-generation-sequencing, using AmpliSeq™ Cancer Hotspot v2 (Life Technologies) and immunohistochemistry (IHC) (AKT-mTOR pathway).
RESULTS: Eleven patients were identified (mean age 41±15 years, sex-ratio 0.8, median follow-up 78 months). Surgical approach was thoracotomy (n=6), sternotomy (n=4), and VATS (n=1). Additional procedures included thymectomy in three cases, mediastinal lymphadenectomy in two cases, and bilobectomy in one case. One patient presented local relapse as a follicular dendritic cell sarcoma, leading to death 48 months after the first resection. Within 9 patients whose FFPE blocks were available, 2 mutations were found: VHL (p.F119L, 35%, n=1) and JAK3 (p.V718L, 53%, n=1). Phospho-AKT and phospho-mTOR stainings were negative in all cases, whereas phospho-S6RP staining was positive in eight cases, mainly in interfollicular cell cytoplasm.
CONCLUSIONS: From this series of patients with unicentric mediastinal CD, we observed 2 cases of potential driver mutations and 8 cases of phospho-S6RP activation not related to AKT-mTOR. Larger studies are required to decipher more precisely the molecular abnormalities and potential therapeutic targets underlying this uncommon condition.

Entities:  

Keywords:  Castleman disease (CD); Mediastinal tumor; molecular biology; tumor biology; tumor markers

Year:  2018        PMID: 29850111      PMCID: PMC5949489          DOI: 10.21037/jtd.2018.03.159

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  23 in total

Review 1.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.

Authors:  Corey Casper
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

2.  Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center.

Authors:  Yujun Dong; Jia Na; Jicheng Lv; Rengui Wang; Xixue Chen; Nan Li; Hanyun Ren
Journal:  Leuk Lymphoma       Date:  2009-08

3.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

4.  Preoperative embolization for the treatment of cervical Castleman disease.

Authors:  Alberto Sanchez-Ros-Sanchez; Pedro Infante-Cossio; Alejandro Gonzalez-Garcia; Juan-Jose Borrero-Martin
Journal:  J Craniofac Surg       Date:  2012-05       Impact factor: 1.046

Review 5.  Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.

Authors:  N Shenoy; L Pagliaro
Journal:  Ann Oncol       Date:  2016-06-20       Impact factor: 32.976

6.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

7.  Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma.

Authors:  H Brauch; G Weirich; M A Hornauer; S Störkel; T Wöhl; T Brüning
Journal:  J Natl Cancer Inst       Date:  1999-05-19       Impact factor: 13.506

8.  Human herpesvirus 8-related Castleman disease in the absence of HIV infection.

Authors:  A Dossier; V Meignin; C Fieschi; D Boutboul; E Oksenhendler; L Galicier
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

9.  [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].

Authors:  Nicolas Pécuchet; Antoine Legras; Pierre Laurent-Puig; Hélène Blons
Journal:  Ann Pathol       Date:  2016-01-20       Impact factor: 0.407

10.  Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro.

Authors:  Merav D Shmueli; Lee Schnaider; Daniel Rosenblum; Gal Herzog; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more
  2 in total

Review 1.  Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.

Authors:  Małgorzata Wojtyś; Agnieszka Piekarska; Michał Kunc; Konrad Ptaszyński; Wojciech Biernat; Jan Maciej Zaucha; Piotr Waloszczyk; Piotr Lisowski; Bartosz Kubisa; Tomasz Grodzki
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

Review 2.  A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.

Authors:  Alexandra Butzmann; Jyoti Kumar; Kaushik Sridhar; Sumanth Gollapudi; Robert S Ohgami
Journal:  Biology (Basel)       Date:  2021-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.